This trial is testing whether adding olaparib after surgery and chemo helps treat pancreatic cancer with a pathogenic mutation in BRCA1, BRCA2, or PALB2.
1 Primary · 8 Secondary · Reporting Duration: Up to 10 years
Experimental Treatment
Non-Treatment Group
152 Total Participants · 2 Treatment Groups
Primary Treatment: Olaparib · Has Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: